These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 32898467

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Strategies for the treatment of polymyxin B-resistant Acinetobacter baumannii infections.
    Menegucci TC, Albiero J, Migliorini LB, Alves JL, Viana GF, Mazucheli J, Carrara-Marroni FE, Cardoso CL, Tognim MC.
    Int J Antimicrob Agents; 2016 May; 47(5):380-5. PubMed ID: 27068675
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Non-polymyxin-based combinations as potential alternatives in treatment against carbapenem-resistant Acinetobacter baumannii infections.
    Mohd Sazlly Lim S, Naicker S, Ayfan AK, Zowawi H, Roberts JA, Sime FB.
    Int J Antimicrob Agents; 2020 Oct; 56(4):106115. PubMed ID: 32721600
    [Abstract] [Full Text] [Related]

  • 8. Pharmacodynamic Effects of Sulbactam/Meropenem/Polymyxin-B Combination Against Extremely Drug Resistant Acinetobacter baumannii Using Checkerboard Information.
    Menegucci TC, Fedrigo NH, Lodi FG, Albiero J, Nishiyama SAB, Mazucheli J, Carrara-Marroni FE, Voelkner NMF, Gong H, Sy SKB, Tognim MCB.
    Microb Drug Resist; 2019 Nov; 25(9):1266-1274. PubMed ID: 31216222
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. In vitro activities of carbapenems in combination with amikacin, colistin, or fosfomycin against carbapenem-resistant Acinetobacter baumannii clinical isolates.
    Singkham-In U, Chatsuwan T.
    Diagn Microbiol Infect Dis; 2018 Jun; 91(2):169-174. PubMed ID: 29433997
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Synergistic killing by meropenem and colistin combination of carbapenem-resistant Acinetobacter baumannii isolates from Chinese patients in an in vitro pharmacokinetic/pharmacodynamic model.
    Liu X, Zhao M, Chen Y, Bian X, Li Y, Shi J, Zhang J.
    Int J Antimicrob Agents; 2016 Nov; 48(5):559-563. PubMed ID: 27670371
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The synergic and addictive activity of biogenic silver nanoparticle associated with meropenem against carbapenem-resistant Acinetobacter baumannii.
    Allend SO, Oliveira Garcia M, da Cunha KF, de Albernaz DTF, Panagio LA, Nakazaro G, Reis GF, Oliveira TL, Neto ACPS, Hartwig DD.
    J Appl Microbiol; 2024 Mar 01; 135(3):. PubMed ID: 38383758
    [Abstract] [Full Text] [Related]

  • 20. In vitro antimicrobial synergy of colistin with rifampicin and carbapenems against colistin-resistant Acinetobacter baumannii clinical isolates.
    Hong DJ, Kim JO, Lee H, Yoon EJ, Jeong SH, Yong D, Lee K.
    Diagn Microbiol Infect Dis; 2016 Oct 01; 86(2):184-9. PubMed ID: 27475960
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.